ENElena I. Nikishova

Elena I. Nikishova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena I. Nikishova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Operational Study of Efficacy and Safety of 9-Month Multi- and Pre-Extesively Drug Resistant Tuberculosis Therapy in the Russian Federation

    by Elena S. Khimova, Grigory V. Volchenkov, Dmitry V. Perkhin, Elena S. Dyzhik, Oksana M. Sveshnikova, Tatyana A. Kuznetsova, Svetlana V. Makhmaeva, Viktoria N. Verkhovaya, Marietta A. Chernykh, Tatyana I. Guryeva, et al.

    Background. The World Health Organization (WHO) recommends conducting regional operational studies of fully oral modified shorter treatment regimens for multidrug/rifampicin-resistant tuberculosis in different countries to achieve an indicator of tuberculosis treatment effectiveness. Aims — to evaluate the efficacy and safety of 9-month, fully oral four-component treatment regimen for patients with MDR and pre-XDR-TB in two administrative regions of the Russian Federation. Methods. In frame of operational research conducted in the Arkhangelsk and Vladimir regions, 167 MDR-TB patients started 9-month treatment. Based on results of drug susceptibility testing of mycobacteria to fluoroquinolones, 134 participans received therapy with combination of levofloxacin (Lfx), bedaquiline (Bdq), linezolid (Lzd), clofazimine (Cfz), one patient — with levofloxacin (Lfx), bedaquiline (Bdq), delamanid (Dlm), clofazimine (Cfz), and 32 patients with — bedaquiline (Bdq), linezolid (Lzd), delamanid (Dlm) and clofazimine (Cfz). The molecular genetic verification of MDR-TB was 98.2%. HIV and hepatitis C co-infection was confirmed for 13.2% and 16.8% of participants, respectively. Adults, two teenagers and a pregnant woman participated in the study. Results. Favorable treatment outcomes were registered for 137 (82%) patients. Two of them had recurrence of the active TB disease. 15 (9%) patients were lost-to-follow-up, 7 (4.2%) patients had failure outcomes, and 8 (4.8%) patients died during treatment. On average, the culture conversion occurred after the first month of treatment. Active safety monitoring revealed 483 adverse events in 167 patients, the most frequent were: hepatotoxic reaction (in 89 patients, 53.3%), anemia (in 62 patients, 37.1%), QT prolongation (in 41 patients, 24.6%), polyneuropathy (in 45 patients, 26.9%). The frequency of serious adverse events was 9.5% of total number of adverse events. Conclusions. The results of an operational study of fully oral 9-month four-component treatment regimens demonstrate the achievement of WHO tuberculosis treatment effectiveness indicators (more than 80%), and low level of serious adverse events. They can be recommended for the national clinical guidelines.


  • Open Access

    Targeted sequencing of drug resistance genes Mycobacterium tuberculosis

    by Igor K. Kovrov, Yuliya A. Popova, Irina A. Popova, Elena I. Nikishova, Andrei O. Mariandyshev

    INTRODUCTION . Drug-resistant forms of tuberculosis and their prevalence are an urgent problem of modern medicine. Genetic mechanisms of drug resistance are the key to understanding the possibilities of diagnostic methods for therapy-resistant tuberculosis. Currently, both phenotypic signs of pathogen resistance to TB drugs and genetic markers of resistance are being identified. A wide range of thematic publications and studies on gene mutations is associated with resistance to TB drugs. OBJECTIVE. Analyze the most effective molecular biological technologies and methods allowing to determine resistance of the tuberculosis pathogen to drugs recommended by the World Health Organization (WHO) in treatment regimens. To present the highest incidence of individual mutations associated with antibiotic resistance genes, which form a significant level of resistance to antituberculosis drugs. Consider the spectrum of mutations of drug resistance genes that provide the greatest contribution to its formation. MATERIALS AND METHODS . Materials of Russian and foreign authors, WHO recommendations related to the prevalence and assessment of the significance of mutations of individual antibiotic resistance genes in different countries and regions were used. Periodical literature sources from international and Russian free databases were analyzed: PubMed, WHO website (https://www.who.int), international tuberculosis database - Tuberculosis Drug Resistance Mutation Database (TBDReaMDB). (http://www.tbdreamdb.com), MDPI, eLIBRARY, CyberLeninka, and a sample of articles by keywords for 20 years (from 2004 to 2024). RESULTS . The most effective molecular biological technologies that enable the detection of mutations in drug resistance genes are presented. Targeted sequencing allows the targeted selection of primers to fragments of genes associated with drug resistance to obtain the results necessary to assess the level of resistance of mycobacteria to the main drugs included in the treatment regimen. The most frequent localizations of mutations in Mycobacterium tuberculosis genes associated with significant levels of drug resistance have been systematized. DISCUSSION. The prevalence of drug-resistant strains varies across countries and regions and can only be compared using a reliable and verifiable genetic method. Targeted sequencing is a method for effective surveillance of drug-resistant TB, and phenotypic testing in the Bactec MGIT system is used to validate this information. Results of the prevalence of single nucleotide polymorphisms obtained by sequencing methods should complement and clarify the data detected by PCR methods. CONCLUSION . Targeted Sanger sequencing of drug resistance genes occupies a worthy place among other molecular genetic methods of tuberculosis research. Targeted sequencing has a special role in the analysis of genes associated with drug resistance to long-standing first-line drugs with atypical localization of mutations; it is also the only method for the study of genes associated with resistance to new and emerging drugs. Adequate selection of primer sets for the regions of drug resistance genes encoding polypeptide chain positions in M. tuberculosis enzyme complexes that are critical for the correct formation of the globular structure plays a key role in the efficiency of Sanger sequencing.

  • Open Access

    Molecular epidemiological monitoring of the tuberculosis pathogen in the Arkhangelsk region

    by Аnna А. Vyazovaya, Platon I. Eliseev, Alena А. Gerasimova, Natalya S. Solovieva, Elena I. Nikishova, Olga V. Narvskaya, Igor V. Mokrousov, Andrey O. Mariandyshev, Соловьёва Наталья Сергеевна, Марьяндышев Андрей Олегович

    Introduction. Against the background of improvement of the main epidemiological indicators (morbidity and mortality) for tuberculosis in the Arkhangelsk region, the proportion of newly diagnosed tuberculosis patients with multidrug-resistant pathogen (MDR-TB) increased from 18.7% in 2002 to 33.8% in 2018. The purpose of this study was the genotypic characterization of Mycobacterium tuberculosis strains obtained from newly diagnosed tuberculosis patients in the Arkhangelsk region in 2018. Materials and methods. 89 M. tuberculosis strains isolated in 2018 from newly diagnosed tuberculosis patients were studied. Beijing genotype, its clusters B0/W148 and Central Asian/Russian were determined by PCR detection of the specific markers: IS6110 insertions in the dnaA-dnaN region, mutations in codons 48 of the mutT4 gene (CGG GGG) and 58 of the mutT2 gene (GGA CGA), IS6110 insertions in the Rv2664 region-Rv2665 and Rv1359-Rv1360, substitutions G A in the sigE gene. Non-Beijing strains were spoligotyped. Results. Drug resistance was detected in 41.6% (37/89), MDR — in 33.7% of strains. In 90% (27/30) of MDR strains, resistance to rifampicin and isoniazid was due to rpoB Ser531Leu and katG Ser315Thr mutations. Following M. tuberculosis genotypes were identified: Beijing (67.4%), T (14.6%), Ural (4.5%), Haarlem (4.5%), LAM (2.3%) and CAS1-Delhi (1.1%). Among the Beijing strains, clusters Central-Asian/Russian (60%; 36/60) and B0/W148 (30%; 18/60) prevailed. The majority of MDR strains belonged to the Beijing family (93.3%; 28/30), of which 64.3% (18/28) and 21.4% (6/28) belonged to clusters B0/W148 and Central-Asian/Russian, respectively. Conclusion. In heterogeneous population of the causative agent of tuberculosis in the Arkhangelsk region, the most common strains were those of the Beijing genotype; in 2018 its share increased to 67.4% (40.4% in 1998–1999). Among MDR strains, the proportion of Beijing reached 93.3%, of which more than half (64.3%) belonged to the epidemiologically and clinically significant in Russia cluster B0/W148.